Table 2 Characteristics of studies included in analysis (n = 174)
Characteristic | Value |
|---|---|
Median sample size (range) | 421 (19–4,312) |
Placebo-controlled | 45 (26 %) |
Intervention type | |
Chemotherapy | 83 (48 %) |
Hormonal therapy | 7 (4 %) |
Targeted therapy | 60 (34 %) |
Immunotherapy | 11 (6 %) |
Chemotherapy + targeted therapy | 7 (4 %) |
Chemotherapy + immunotherapy | 6 (3 %) |
Trial met primary endpoint | 75 (43 %) |
Funding source | |
Industry | 112 (64 %) |
Government | 16 (9 %) |
Industry and Government | 14 (8 %) |
Other | 9 (5 %) |
Funding source not reported | 22 (13 %) |
No funding | 1 (<1 %) |
Experimental drug approved for other indication | 132 (76 %) |
Year of publication | |
2009 | 49 (28 %) |
2010 | 58 (33 %) |
2011 | 67 (39 %) |
Cancer type | |
Breast | 37 (21 %) |
Colorectal | 19 (11 %) |
Gastric or gastroesophageal | 8 (5 %) |
Head and neck | 5 (3 %) |
Lung | 37 (21 %) |
Melanoma | 9 (5 %) |
Ovarian | 12 (7 %) |
Pancreas | 11 (6 %) |
Prostate | 9 (5 %) |
Renal | 8 (5 %) |
Other | 19 (11 %) |
Journal | |
Annals of Oncology | 16 (9 %) |
Breast Cancer Research and Treatment | 6 (3 %) |
British Journal of Cancer | 3 (2 %) |
Cancer | 5 (3 %) |
European Journal of Cancer | 10 (6 %) |
Journal of Clinical Oncology | 60 (34 %) |
Lancet | 11 (6 %) |
Lancet Oncology | 12 (7 %) |
New England Journal of Medicine | 14 (8 %) |
Other | 37 (21 %) |
Impact factor of journals, median (range) | 18 (1–53) |